On The Pulse - 11th December 2015
Empagliflozin in type 2 diabetes (Source: OnMedica Blogs)
Source: OnMedica Blogs - December 11, 2015 Category: Journals (General) Source Type: blogs
Cutting through the Jardiance Study Hype: Be Cautious with this Drug!
(Source: Diabetes Update)
Source: Diabetes Update - September 18, 2015 Category: Endocrinology Source Type: blogs
Sanjay Kaul On The Empa-Reg Outcome Study
The really big medical news today is the publication of the highly anticipated Empa-Reg Outcome study in the New England Journal of Medicine. It is the first large clinical trial with a diabetes drug (empagliflozin, Jardiance) to demonstrate a significant reduction in cardiovascular outcomes. The trial even resulted in a surprising, statistically significant reduction in mortality. I asked Sanjay Kaul for...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 17, 2015 Category: Cardiology Authors: Larry Husten Tags: Diabetes Heart Failure People, Places & Events Prevention, Epidemiology & Outcomes CVOT empaglifloz Jardiance SGLT2 Source Type: blogs
Wow! Maybe– Finally– A Positive Diabetes Drug Outcomes Trial
Until now the best thing anyone could say for sure about all the new diabetes drugs was that at least they didn’t kill people. That’s because although these drugs have been shown to be highly effective in reducing glucose levels, a series of large cardiovascular outcomes trials failed to provide any evidence of significant clinical...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 20, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes Uncategorized boehringer infelheim cardiovascular outcomes diabetes empagliflozin Lilly Source Type: blogs
Public Citizen Urges FDA To Penalize Drug Makers Over Diabetes Ads, Criticizes the Agency’s “Dismal Record” on Issuing Warning Letters
Consumer advocacy group Public Citizen is calling on the Food and Drug Administration (FDA) to “stop the apparently violative off-label promotional statements” in various Type 2 Diabetes advertisements, which the group argues are being advertised as weight-loss drugs. “[N]one of the drugs is approved for weight loss and, despite the presence of disclaimers that the medications are not weight-loss drugs, the implication is clearly that weight loss is an additional potential benefit of the drugs,” Public Citizen states.
This request comes in the midst of a “drastic reduction” in the past few years of direct-to-co...
Source: Policy and Medicine - April 3, 2015 Category: American Health Authors: Thomas Sullivan Source Type: blogs
FDA Approves New Oral Drug for Type 2 Diabetes
By Diane Fennell
On August 1, the US Food and Drug Administration (FDA) approved the oral diabetes drug Jardiance (generic name empagliflozin) for use, along with a healthful diet and exercise, in adults with Type 2 diabetes. The medicine, a joint development of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, joins Invokana (canagliflozin) and Farxiga (dapagliflozin) as a member of the class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.
In the process of filtering the blood, the kidneys typically reabsorb all the filtered glucose and return it to the bloodstream. One of the main pr...
Source: Diabetes Self-Management - August 8, 2014 Category: Diabetes Authors: Diane Fennell Source Type: blogs
Salary Freeze at Lilly
We now return to our regularly schedule program around here - or at least, Eli Lilly is now returning to theirs. The company announced that they're freezing salaries for most of the work force, in an attempt to save hundreds of millions of dollars in advance of their big patent expirations. Some bonuses will be reduced as well, they say, but that leaves a lot of room. Higher-ups don't look for increases in base pay as much as they look for bonuses, options, and restricted shares (although, to be fair, these are often awarded as a per cent of salary).
‘‘This action is necessary to withstand the impact of upcoming paten...
Source: In the Pipeline - July 19, 2013 Category: Chemists Tags: Business and Markets Source Type: blogs
